drugset / Trial / NCT04256525

Prophylactic Anticoagulation for Catheter-related Thrombosis

NCT04256525

RandomizedParallel-groupOpen-labelPrevention

Summary

The main objective of this study is to compare the efficacy and safety of aspirin, low molecule heparin and rivaroxaban for preventing catheter-related thrombosis in middle-to-high-risk ambulatory patients with cancer and implantable venous access ports.

Timeline

Start
2020-05-01
Primary completion
2021-08-30
Completion
2022-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 100 mg Oral
Subject Rivaroxaban Other / unclassified 10 mg Oral
Subject low molecule heparin Unknown 0.4 ml Subcutaneous